|
DE2245404C3
(de)
|
1972-09-15 |
1978-08-31 |
Robert Bosch Gmbh, 7000 Stuttgart |
Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
|
|
JPS531908B2
(https=)
|
1973-11-12 |
1978-01-23 |
|
|
|
JPS5746634B2
(https=)
|
1974-05-10 |
1982-10-04 |
|
|
|
JPS5146628A
(ja)
|
1974-10-17 |
1976-04-21 |
Nippon Denso Co |
Teikoirisupaakupuragu
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
EP1025230B1
(en)
|
1997-12-01 |
2006-02-08 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE
|
|
DE19818214A1
(de)
|
1998-04-24 |
1999-10-28 |
Bosch Gmbh Robert |
Zündkerze für eine Brennkraftmaschine
|
|
EP2011801A1
(en)
|
1999-05-27 |
2009-01-07 |
Government of the United States as represented by the Secretary, Department of Health and Human Services |
Immunoconjugates having high binding affinity
|
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
|
JP4578025B2
(ja)
|
2001-07-06 |
2010-11-10 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
EP1699826B1
(en)
|
2005-01-05 |
2009-03-11 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
EP2399935A3
(en)
|
2005-02-15 |
2012-02-22 |
GTC Biotherapeutics, Inc. |
An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
|
|
EP1861425B1
(en)
|
2005-03-10 |
2012-05-16 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
GB0624500D0
(en)
|
2006-12-07 |
2007-01-17 |
Istituto Superiore Di Sanito |
A novel passive vaccine for candida infections
|
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
|
MX2010005603A
(es)
|
2007-11-26 |
2010-08-02 |
Bayer Schering Pharma Ag |
Anticuerpos antimesotelina y usos de los mismos.
|
|
PT2594590E
(pt)
|
2007-12-14 |
2015-01-14 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010057047A1
(en)
|
2008-11-13 |
2010-05-20 |
Trubion Pharmaceutics, Inc. |
Cd37 immunotherapeutic combination therapies and uses thereof
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
EP2411416A1
(en)
|
2009-03-24 |
2012-02-01 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Anti-mesothelin antibodies
|
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
EP2407487A1
(en)
|
2010-07-14 |
2012-01-18 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Multispecific modular antibody
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
BR112013014527A2
(pt)
|
2010-12-20 |
2017-03-07 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
EP2546268A1
(en)
|
2011-07-13 |
2013-01-16 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Internalising immunoglobulin
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
JP5276742B1
(ja)
|
2012-08-09 |
2013-08-28 |
日本特殊陶業株式会社 |
点火プラグ
|
|
CN104955845B
(zh)
*
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
|
EP3508215A3
(en)
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
US10344088B2
(en)
|
2013-03-15 |
2019-07-09 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
US11634502B2
(en)
|
2013-03-15 |
2023-04-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
GB201317622D0
(en)
|
2013-10-04 |
2013-11-20 |
Star Biotechnology Ltd F |
Cancer biomarkers and uses thereof
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US20150307620A1
(en)
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
WO2015198312A1
(en)
|
2014-06-24 |
2015-12-30 |
Ccam Therapeutics Ltd. |
Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
|
|
JP5902757B2
(ja)
|
2014-06-24 |
2016-04-13 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
WO2016025379A1
(en)
|
2014-08-10 |
2016-02-18 |
Federal-Mogul Ignition Company |
Spark plug with improved seal
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
CA2874083C
(en)
|
2014-12-05 |
2024-01-02 |
Universite Laval |
Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
|
|
SI3242890T1
(sl)
|
2015-01-08 |
2020-01-31 |
BioNTech SE |
Agonistična sredstva, ki vežejo receptorje TNF
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
KR20180016972A
(ko)
|
2015-02-22 |
2018-02-20 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Cd137에 결합하는 항체 치료제
|
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
Ｆ 星生物科技有限公司 |
Ｈｅｒ２結合劑治療
|
|
JP6783797B2
(ja)
|
2015-05-04 |
2020-11-11 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
抗がん融合ポリペプチド
|
|
CN114181309B
(zh)
|
2015-05-21 |
2024-07-30 |
鳄鱼生物科学公司 |
新型多肽
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
JP6025921B1
(ja)
|
2015-06-22 |
2016-11-16 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
WO2017009456A1
(en)
|
2015-07-15 |
2017-01-19 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for lag-3
|
|
CN114853891A
(zh)
|
2015-07-22 |
2022-08-05 |
索伦托药业有限公司 |
与lag3结合的抗体治疗剂
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
CA2994631A1
(en)
|
2015-08-07 |
2017-02-16 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptide specific for lag-3 and pd-1
|
|
JP6845846B6
(ja)
|
2015-09-22 |
2021-04-21 |
ディンフー バイオターゲット カンパニー リミテッド |
抗ヒトｃｄ１３７の完全ヒト抗体及びその用途
|
|
KR101782487B1
(ko)
*
|
2015-09-24 |
2017-09-27 |
재단법인 목암생명과학연구소 |
신규 항-메소텔린 항체 및 이를 포함하는 조성물
|
|
US10526413B2
(en)
|
2015-10-02 |
2020-01-07 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specific for OX40
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
GB201519481D0
(en)
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
|
IL300122A
(en)
|
2015-11-18 |
2023-03-01 |
Merck Sharp ַ& Dohme Llc |
Substances that bind to PD1 and/or LAG3
|
|
US20190330336A1
(en)
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
|
KR20180096789A
(ko)
|
2016-01-11 |
2018-08-29 |
인히브릭스, 인크. |
다가 및 다중특이적 41bb-결합 융합 단백질
|
|
JP6365802B2
(ja)
|
2016-03-18 |
2018-08-01 |
大日本印刷株式会社 |
中間転写媒体と熱転写シートとの組合せ、及び印画物の形成方法
|
|
EP3445788B1
(en)
*
|
2016-04-22 |
2022-01-19 |
Alligator Bioscience AB |
Novel bispecific polypeptides against cd137
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
BR112018074453A2
(pt)
|
2016-05-27 |
2019-03-19 |
Abbvie Biotherapeutics Inc. |
proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
|
|
US20190106494A1
(en)
|
2016-06-13 |
2019-04-11 |
Askgene Pharma Inc. |
PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
CN107523546A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抗体的nk细胞及其用途
|
|
HRP20210602T1
(hr)
|
2016-06-20 |
2021-05-14 |
F-Star Delta Limited |
Vezujuće molekule koje vežu pd-l1 i lag-3
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
CN109715666B
(zh)
|
2016-07-20 |
2023-02-21 |
斯特库比股份有限公司 |
癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
|
|
ES2981272T3
(es)
|
2016-09-23 |
2024-10-08 |
Merus Nv |
Moléculas de unión que modulan una actividad biológica expresada por una célula
|
|
GB201616699D0
(en)
|
2016-09-30 |
2016-11-16 |
Mab Designs Ltd |
Antibodies
|
|
GB201619648D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
GB201700345D0
(en)
|
2017-01-09 |
2017-02-22 |
F-Star Beta Ltd |
Conditional agonists of immune responses
|
|
US11260117B2
(en)
|
2017-05-26 |
2022-03-01 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
|
JP2020522495A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
EP3728316B1
(en)
|
2017-12-19 |
2025-02-26 |
invoX Pharma Limited |
Fc binding fragments comprising a pd-l1 antigen-binding site
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
ES3044118T3
(en)
|
2018-07-12 |
2025-11-26 |
Invox Pharma Ltd |
Antibody molecules that bind cd137 and ox40
|
|
PT3820569T
(pt)
|
2018-07-12 |
2025-01-14 |
Invox Pharma Ltd |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
AU2020275209A1
(en)
|
2019-05-14 |
2021-12-23 |
F-Star Therapeutics Limited |
Dosage regimes for the administration of a LAG-3/PD-L1 bispecific antibody
|